Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
Management
Stefano Rossetti
- Vice President, Clinical Development & Regulatory Affairs
Stefano Rossetti has been the Company’s Vice President of Development since May 2003. Dr. Rossetti holds a degree in medicine and surgery and gastroenterology from Pavia and Milan Universities and is the author of several scientific publications. From 1999 to 2003, he was Director of Product Development at Schering-Plough Pharmaceuticals International (Europe/Canada/Middle East) with regulatory, medical and commercial responsibilities during the new drugs development process (from early development phase to registration and market positioning). From 1989 to 1999, Dr Rossetti was Medical and Regulatory Affairs Director at Schering-Plough Italy. From 1984 to 1989, he was the Medical Director for SyntheLabo Italy with specific responsibilities in the cardiovascular, CNS and pneumology areas. From 1981 to 1984, Dr Rossetti was the clinical monitor for Boots Italy conducting and monitoring phase II, III and IV clinical trials in the gastroenterology, rheumatology, trauma and cardiovascular area and CNS.